{"id":55509,"date":"2026-01-26T20:55:30","date_gmt":"2026-01-26T12:55:30","guid":{"rendered":"https:\/\/flcube.com\/?p=55509"},"modified":"2026-01-26T20:55:31","modified_gmt":"2026-01-26T12:55:31","slug":"dizal-pharmaceutical-files-for-hong-kong-ipo-backed-by-astrazeneca-and-first-in-class-oncology-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55509","title":{"rendered":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets"},"content":{"rendered":"\n<p><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>), the <strong>China\u2011based joint venture<\/strong> established by <strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) and <strong>Future Industry Investment Fund<\/strong> in November\u202f2017, announced it has <strong>filed for an initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, seeking to raise capital to expand its commercial footprint for <strong>two globally unique oncology therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-overview\">IPO Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Dizal Pharmaceutical Co., Ltd. (688192.SH)<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 13\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>JV Structure<\/strong><\/td><td>AstraZeneca (NASDAQ:\u202fAZN) + Future Industry Investment Fund (est. Nov\u202f2017)<\/td><\/tr><tr><td><strong>Spin\u2011Out<\/strong><\/td><td>Independent operations since end\u20112017<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Oncology and hematological diseases<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Commercial expansion, pipeline advancement, manufacturing scale\u2011up<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-portfolio-first-in-class-assets\">Commercial Portfolio: First\u2011in\u2011Class Assets<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Generic Name<\/th><th>Indication<\/th><th>Global Position<\/th><th>9M\u202f2025 Revenue<\/th><\/tr><\/thead><tbody><tr><td><strong>Shuwozhe<\/strong><\/td><td>Sunvozertinib<\/td><td>NSCLC with EGFR exon\u202f20 insertion mutations<\/td><td><strong>World\u2019s only<\/strong> small\u2011molecule EGFR TKI for this mutation<\/td><td>RMB\u202f586\u202fM total (both products)<\/td><\/tr><tr><td><strong>Gaoruizhe<\/strong><\/td><td>Golidocitinib<\/td><td>Relapsed\/refractory peripheral T\u2011cell lymphoma (r\/r PTCL)<\/td><td><strong>World\u2019s first and only<\/strong> approved JAK1 inhibitor for PTCL<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shuwozhe (Sunvozertinib):<\/strong> Addresses <strong>EGFR exon\u202f20 insertion mutations<\/strong> (3\u20115\u202f% of NSCLC patients), a population historically resistant to conventional EGFR TKIs<\/li>\n\n\n\n<li><strong>Gaoruizhe (Golidocitinib):<\/strong> Targets <strong>JAK1<\/strong> in PTCL, offering a <strong>targeted therapy<\/strong> where chemotherapy has failed, with <strong>manageable safety profile<\/strong> vs. pan\u2011JAK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-development\">Pipeline &amp; Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Stage<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Birelentinib<\/strong><\/td><td>Lyn\/BTK dual inhibitor<\/td><td>Regulatory clinical phase<\/td><td>Hematological malignancies<\/td><\/tr><tr><td><strong>3 undisclosed assets<\/strong><\/td><td>Various<\/td><td>Post\u2011proof\u2011of\u2011concept<\/td><td>Oncology<\/td><\/tr><tr><td><strong>1 undisclosed asset<\/strong><\/td><td>Various<\/td><td>Early clinical<\/td><td>Oncology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Birelentinib:<\/strong> Dual inhibition of <strong>Lyn and BTK<\/strong> aims to overcome resistance in <strong>B\u2011cell malignancies<\/strong>; NDA submission targeted for <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Platform Advantage:<\/strong> Leverages AstraZeneca\u2019s legacy R&amp;D infrastructure while maintaining <strong>independent China\u2011centric development<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance\">Financial Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>9M\u202f2025<\/th><th>FY\u202f2024 (Est.)<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>RMB\u202f586\u202fmillion (USD\u202f84\u202fmillion)<\/td><td>~RMB\u202f750\u202fmillion<\/td><\/tr><tr><td><strong>Growth Rate<\/strong><\/td><td>45\u202f% YoY<\/td><td>38\u202f% YoY<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>82\u202f%<\/td><td>80\u202f%<\/td><\/tr><tr><td><strong>Commercial Team<\/strong><\/td><td>450 reps covering 1,800 hospitals<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profitability Path:<\/strong> Revenue growth driven by <strong>Shuwozhe uptake<\/strong> in tier\u20111\/2 cities and <strong>Gaoruizhe<\/strong> inclusion in <strong>NRDL<\/strong> (National Reimbursement Drug List) in 2024<\/li>\n\n\n\n<li><strong>Valuation:<\/strong> IPO expected to value Dizal at <strong>RMB\u202f8\u201110\u202fbillion<\/strong> (USD\u202f1.1\u20111.4\u202fbillion) based on comparable China biotech multiples<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AstraZeneca Backing:<\/strong> JV structure provides <strong>technology transfer access<\/strong>, <strong>global development expertise<\/strong>, and <strong>commercial credibility<\/strong><\/li>\n\n\n\n<li><strong>China Market Focus:<\/strong> <strong>First\u2011in\u2011class positioning<\/strong> in niche oncology segments (EGFR exon\u202f20, PTCL) with limited competition<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> <strong>Suzhou facility<\/strong> (capacity 50\u202fmillion tablets\/year) supports commercial supply; <strong>biologics expansion<\/strong> planned for 2027<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Rights to <strong>ex\u2011China licensing<\/strong> for select pipeline assets; AstraZeneca retains <strong>co\u2011promotion rights<\/strong> in certain markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO completion, valuation ranges, and commercial forecasts for Dizal\u2019s oncology portfolio. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in the NSCLC and PTCL markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012301156_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26012301156_c.\"><\/object><a id=\"wp-block-file--media-5cbbcce0-77ce-4706-abb2-0b5cd93a9875\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012301156_c.pdf\">sehk26012301156_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012301156_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5cbbcce0-77ce-4706-abb2-0b5cd93a9875\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[130,770,191,72,871,981],"class_list":["post-55509","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astrazeneca","tag-az","tag-dizal-pharmaceutical","tag-ipo","tag-nasdaq-azn","tag-sha-688192"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55509\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55509\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T12:55:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T12:55:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets\",\"datePublished\":\"2026-01-26T12:55:30+00:00\",\"dateModified\":\"2026-01-26T12:55:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509\"},\"wordCount\":464,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"Dizal Pharmaceutical\",\"IPO\",\"NASDAQ: AZN\",\"SHA: 688192\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55509#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55509\",\"name\":\"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T12:55:30+00:00\",\"dateModified\":\"2026-01-26T12:55:31+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55509\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55509#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55509","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.","og_url":"https:\/\/flcube.com\/?p=55509","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T12:55:30+00:00","article_modified_time":"2026-01-26T12:55:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55509#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55509"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets","datePublished":"2026-01-26T12:55:30+00:00","dateModified":"2026-01-26T12:55:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55509"},"wordCount":464,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","Dizal Pharmaceutical","IPO","NASDAQ: AZN","SHA: 688192"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55509#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55509","url":"https:\/\/flcube.com\/?p=55509","name":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T12:55:30+00:00","dateModified":"2026-01-26T12:55:31+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China\u2011based joint venture established by AstraZeneca (AZ, NASDAQ:\u202fAZN) and Future Industry Investment Fund in November\u202f2017, announced it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, seeking to raise capital to expand its commercial footprint for two globally unique oncology therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55509#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55509"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55509#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First\u2011in\u2011Class Oncology Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55509"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55509\/revisions"}],"predecessor-version":[{"id":55512,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55509\/revisions\/55512"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}